Drug Profile
FOL 005
Alternative Names: FOL-005; Osteopontin derived peptide - Coegin PharmaLatest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Follicum AB
- Developer Coegin Pharma
- Class Cytokines; Peptides; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alopecia
- Preclinical Wounds
Most Recent Events
- 14 Sep 2022 Preclinical trials in Wounds in Norway (Topical), as of September 2022 (Coegin Pharma website, September 2022)
- 14 Sep 2022 Coegin Pharma plans an investigator initiated phase IIa trial for Wounds in Norway (Coegin Pharma website, September 2022)
- 01 Sep 2022 Phase-II clinical trials in Alopecia in Germany (Intradermal) (Coegin Pharma pipeline, September 2022)